Clene Inc. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Clene submitted a New Drug Application (NDA) to the FDA in October 2026 seeking accelerated approval for CNM-Au8 in ALS, supported by Phase 2 HEALEY and RESCUE-ALS trial data. The company completed a $4.0M registered direct offering in September 2026 at $3.28/share to existing stockholders (led by Chairman David Matlin and Kensington Capital Holdings), with cash on hand of $9.9M as of Sept 30, 2026, expected to fund operations through mid-Q1 2027. Clene plans to initiate Phase 3 RESTORE-ALS confirmatory trial in Q2 2027 with survival as primary endpoint.
Why this rating
NDA submission is transformational milestone for $40M-market-cap biotech; $4M raise is 10% of market cap; cash runway still tight, but regulatory milestone significantly de-risks lead program.
Tradability signal
NO TRADE
No trade: positive news with only +0.9% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: +0.08% over 4 hrs, n=359). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $3.81 | +10 min · unknown $3.81 ▲ 0.00% | +30 min · unknown $3.81 ▲ 0.00% | +1 hr · unknown $3.89 ▲ 2.23% | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.